Business

TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia

UNITY-CLL trial met the primary endpoint of improved progression-free survival (PFS)

articleTg Therapeutics, Inc.May 5, 20205/company/tg-therapeutics-inc/news/tg-therapeutics-announces-positive-topline-results-from-the-unity-cll-phase-3-study-evaluating-the-combination-of-umbralisib-and-ublituximab-u2-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia

TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia

About this update from Tg Therapeutics, Inc.

[{"type":"text","content":"UNITY-CLL trial met the primary endpoint of improved progression-free survival (PFS) (p","length":94,"tagName":"div"}]

More updates from Tg Therapeutics, Inc.